CM
Cosmo Pharmaceuticals N.V.
CMOPF · OTC
$68.00 +4.62% (+$3.00)
1M -5.11%
Market Cap 985.0M €
P/E Ratio -
Div. Yield 3.79%
ROE 0.72%
Bulios Fair Price
$39.26
42.3% downside
Current Price
$68
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CMOPF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
19 /100
Expensive P/B 2.04x
EV/EBITDA 396.26x
P/S 9.40x
Growth
26 /100
Declining Book val. growth 1.78%
Rev. growth 0.88%
FCF growth N/A
Profitability
19 /100
Weak Op. margin 10.00%
Gross margin 46.53%
FCF margin 15.12%
Quality
3 /100
Poor ROA 0.59%
ROIC 6.79%
Asset turnover 0.17x
Debt
80 /100
Low Int. coverage -57.54x
Debt/Equity 0.01x
Net debt/EBITDA -21.88x
Stability
9 /100
Unstable EPS volatility 1,637.15%
Beta 1.49x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CMOPF
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Giovanni di Napoli
Employees
324
Headquarters
Dublin
Upcoming events
24 MAR
Earnings
Upcoming earnings report